1251 Cancer in pregnancy: maternal and fetal outcomes

Introduction/Background Cancer complicates approximately 0.1 % of pregnancies. Balancing the risks for mother and baby represents a challenge in the management of these patients. The study reports our experience in oncological and obstetrical care in patients with cancer in pregnancy (CIP), focusing on fetal outcomes. Methodology A retrospective observational cohort study was carried out in our institution 'IRCCS Policlinico Milano', including women with CIP between 2005 and 2023; oncological, obstetrical and neonatal data were collected from 114 cases, 14 were excluded for incomplete data. Results The most common cancer was breast cancer (76%). In most cases diagnosis was made at early stage, except for three cases (IV stage lung cancer, III stage Hodgkin lymphoma, III stage ovarian cancer). Patients' characteristics are shown in Table 1. After multidisciplinary consultancy, patients were encouraged to continue pregnancy and to receive cancer treatment. Therapeutic options during pregnancy are limited by the need to protect fetal development. The options available are chemotherapy, surgery, or a combination of the two. Pregnancy management included standard prenatal care, regular ultrasound evaluation of fetal growth to identify precocious fetal growth restriction and assessment of fetal wellbeing after every chemotherapy administration. The mean gestational age at delivery was 36 weeks. Delivery was elective in 66% of cases and the mode of delivery was C- section in 64%. Placental tissue was collected for histological analysis. No maternal or neonatal deaths were observed. Only seven babies required intensive care because of IUGR (Intrauterine Growth Restriction) or prematurity. Children with IUGR represented 14% of the total; among them, late IUGR children were 71 %. Conclusion Cancer in pregnancy is a rare but progressively increasing event and a multidisciplinary experienced team, including oncologists, obstetricians and neonatologists is crucial. Our data is reassuring, demonstrating good maternal and fetal outcomes, without substantial adverse effects on pregnancy. Disclosures No conflict of interest.